Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

被引：0
作者：
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
机构：
[1] University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
[2] Medical Oncology Unit,Department of Radiation Oncology
[3] Institut de Cancerologie de L’Ouest,INSERM
[4] University Hospital of Nantes,Pneumology Unit
[5] Medical Oncology Unit,Radiology Unit
[6] University Hospital of Nantes,undefined
[7] University Hospital of Nantes,undefined
[8] INSERM,undefined
[9] CRCINA,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Baseline tumour size; Non-small cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1756
页数：9
相关论文
共 50 条
[41]   Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy [J].
Ge, Wenzhen ;
Wu, Ning ;
Jalbert, Jessica J. ;
Quek, Ruben G. W. ;
Liu, Jinjie ;
Rietschel, Petra ;
Pouliot, Jean-Francois ;
Harnett, James ;
Hsu, Melinda Laine ;
Feliciano, Josephine L. .
CANCER MANAGEMENT AND RESEARCH, 2022, 14 :3191-3202
[42]   Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer [J].
Mouri, Atsuto ;
Kaira, Kyoichi ;
Yamaguchi, Ou ;
Hashimoto, Kosuke ;
Miura, Yu ;
Shiono, Ayako ;
Kawasaki, Tomonori ;
Kobayashi, Kunihiko ;
Imai, Hisao ;
Kagamu, Hiroshi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) :124-133
[43]   Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer [J].
Atsuto Mouri ;
Kyoichi Kaira ;
Ou Yamaguchi ;
Kosuke Hashimoto ;
Yu Miura ;
Ayako Shiono ;
Tomonori Kawasaki ;
Kunihiko Kobayashi ;
Hisao Imai ;
Hiroshi Kagamu .
International Journal of Clinical Oncology, 2024, 29 :124-133
[44]   Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy [J].
Li, Lingling ;
Pi, Chenghui ;
Yan, Xin ;
Lu, Jiangyue ;
Yang, Xuhui ;
Wang, Chunyu ;
Li, Xiaoyan ;
Zhang, Sujie ;
Zhang, Zhibo ;
Sun, Yi ;
Hu, Yi .
FRONTIERS IN ONCOLOGY, 2021, 11
[45]   PD-L1 Expression in Patients with Non-small Cell Lung Cancer [J].
Masago, Katsuhiro ;
Fujita, Shiro ;
Hata, Akito ;
Okuda, Chiyuki ;
Kaji, Reiko ;
Katakami, Nobuyuki ;
Hirata, Yukio .
ANTICANCER RESEARCH, 2017, 37 (05) :2269-2274
[46]   Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer [J].
Jahan, N. ;
Swarup, S. ;
Sultan, A. ;
Naing, T. ;
Mogollon-Duffo, F. ;
Ball, S. ;
Tun, A. ;
Htut, T. ;
Dash, A. ;
D'Cunha, N. ;
Hardwicke, F. ;
Awasthi, S. ;
Tijani, L. ;
Thein, K. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S917-S918
[47]   Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study [J].
Gumus, Mahmut ;
Chen, Chieh-, I ;
Ivanescu, Cristina ;
Kilickap, Saadettin ;
Bondarenko, Igor ;
Ozguroglu, Mustafa ;
Gogishvili, Miranda ;
Turk, Haci M. ;
Cicin, Irfan ;
Harnett, James ;
Mastey, Vera ;
Naumann, Ulrike ;
Reaney, Matthew ;
Konidaris, Gerasimos ;
Sasane, Medha ;
Brady, Keri J. S. ;
Li, Siyu ;
Gullo, Giuseppe ;
Rietschel, Petra ;
Sezer, Ahmet .
CANCER, 2023, 129 (01) :118-129
[48]   Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer [J].
La-Beck, Ninh M. ;
Nguyen, Dung T. ;
Le, Alex D. ;
Alzghari, Saeed K. ;
Trinh, Saralinh T. .
PHARMACOTHERAPY, 2020, 40 (03) :239-255
[49]   First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis [J].
Liu, Qiao ;
Zhou, Zhen ;
Luo, Xia ;
Yi, Lidan ;
Peng, Liubao ;
Wan, Xiaomin ;
Tan, Chongqing ;
Zeng, Xiaohui .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[50]   Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis [J].
Ikezawa, Yasuyuki ;
Morita, Ryo ;
Mizugaki, Hidenori ;
Tateishi, Kazunari ;
Yokoo, Keiki ;
Sumi, Toshiyuki ;
Kikuchi, Hajime ;
Kitamura, Yasuo ;
Nakamura, Atsushi ;
Kobayashi, Maki ;
Aso, Mari ;
Kimura, Nozomu ;
Yoshiike, Fumiaki ;
Megumi, Furuta ;
Tanaka, Hisashi ;
Sekikawa, Motoki ;
Hachiya, Tsutomu ;
Nakamura, Keiichi ;
Hommura, Fumihiro ;
Sukoh, Noriaki ;
Ito, Kenichiro ;
Kikuchi, Takashi ;
Agatsuma, Toshihiko ;
Yokouchi, Hiroshi .
CANCER MEDICINE, 2024, 13 (14)
12345